DGNX vs RXRX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
RXRX Captures Institutional Edge (2โ1 Pillars ยท 5โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) driven by superior Growth & Margin, Momentum & Technical while DGNX counters with relative strength in Options & Structure. Fundamentally, DGNX trades at N/M Forward P/E with -546.3% operating margin (+3.3% YoY revenue) versus RXRX at N/M Forward P/E and -734.2% operating margin (+258.5% YoY). In options structure, DGNX sits in BREAKDOWN (51st %ile IV; Dealer Gamma Walls on Pro) against RXRX sits in BREAKDOWN (61st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | DGNX | RXRX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $63.7M | $2.1B | Larger Scale | RXRX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +3.3% | +258.5% | Higher Growth | RXRX |
| Operating Margin (TTM) Profitability | -546.3% | -734.2% | Higher Margin | DGNX |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -250.4% | -48.7% | Higher ROE | RXRX |
| 52-Week Range Position Momentum | 4% ($0โ$18) | 6% ($3โ$5) | Stronger Trend | RXRX |
| Beta / 30D Volatility Risk Regime | 0.04ฮฒ ยท 100% Vol | 3.01ฮฒ ยท 85% Vol | Lower Realized Risk | RXRX |
| Unified Institutional Score Composite Signal | 49.7 / 100 (HOLD) | 49.5 / 100 (HOLD) | Higher Composite | DGNX |